• BCL-XL Inhibitor A-1155463: Precision Apoptosis in Cancer Mo

  2026-06-15

  A-1155463, a highly selective BCL-XL inhibitor, empowers researchers to dissect apoptosis mechanisms and surmount drug resistance in solid tumors and hematological malignancies. This guide details optimal experimental workflows, troubleshooting strategies, and translational insights from recent glioblastoma studies, positioning A-1155463 as an essential tool in advanced cancer biology.

• Moxidectin: Redefining Antiparasitic and Antifungal Synergy

  2026-06-15

  This thought-leadership article explores how moxidectin, a macrocyclic lactone anthelmintic, is transforming both veterinary and antifungal translational research. Integrating mechanistic insights, new evidence for synergy with polyene antifungals, and strategic guidance, we chart a credible path for leveraging APExBIO's high-purity moxidectin in the fight against drug-resistant infections. The article uniquely bridges domains and protocol guidance, offering translational researchers actionable perspectives not found in standard product descriptions.

• ECL Chemiluminescent Substrate Detection Kit: Advancing Tumo

  2026-06-14

  Explore how the ECL Chemiluminescent Substrate Detection Kit (Hypersensitive) unlocks new frontiers in immunoblotting detection of low-abundance proteins, with a special focus on tumor microenvironment research. This article reveals scientific strategies and practical protocols distinct from standard reviews.

• Optimized iPSC Platelet Differentiation: Protocol Innovation

  2026-06-13

  This study presents an optimized protocol for generating functional platelets from human induced pluripotent stem cells (hiPSCs), significantly improving yield, reducing time, and cutting costs compared to conventional approaches. By integrating higher initial embryoid body cell counts, medium refinements, and strategic use of small molecules, the protocol advances scalable platelet production for research and therapeutic applications.

• BMS-777607: Precision c-Met Inhibitor for Platelet & Cancer

  2026-06-12

  BMS-777607 stands out as a potent, selective c-Met inhibitor that bridges advanced cancer metastasis models with innovative hiPSC-derived platelet protocols. This guide translates bench data and reference breakthroughs into actionable workflows, troubleshooting insights, and strategic advantages for researchers targeting MET signaling.

• G007-LK Tankyrase 1/2 Inhibitor: Precision Tools for Wnt and

  2026-06-12

  G007-LK unlocks advanced modulation of the Wnt/β-catenin and Hippo/YAP pathways in APC mutation colorectal and hepatocellular carcinoma research, offering unmatched selectivity and cellular activity. With robust in vitro and in vivo efficacy, this APExBIO reagent enables researchers to dissect tumor signaling with quantitative confidence.

• SARS-CoV-2 N Protein Suppresses GADD34-Mediated Innate Immun

  2026-06-11

  This study reveals how the SARS-CoV-2 nucleocapsid protein impairs host innate immunity by sequestering GADD34 mRNA into atypical stress granule-like foci, thus inhibiting interferon production. These findings deepen understanding of viral immune evasion and highlight mechanistic targets for antiviral research.

• MALAT1 Modulates PCT Expression via miR-125b/STAT3 in Sepsis

  2026-06-11

  This study uncovers how the long non-coding RNA MALAT1 regulates procalcitonin (PCT) levels in sepsis through a miR-125b/STAT3-dependent mechanism. The research clarifies a molecular axis critical to sepsis biomarker regulation, offering new insight for diagnostic and therapeutic strategies.

• Bile Acid Retention Disrupts Antigen Presentation in MASH-HC

  2026-06-10

  This study uncovers a mechanistic link between bile acid retention and impaired antigen presentation in metabolic dysfunction-associated steatohepatitis-related hepatocellular carcinoma (MASH-HCC). The findings demonstrate that targeting bile acid metabolism can restore tumor immunogenicity and enhance response to immune checkpoint blockade, offering new directions for immunotherapy-resistant liver cancer.

• ECL Chemiluminescent Substrate Detection Kit: Sensitivity &

  2026-06-10

  The ECL Chemiluminescent Substrate Detection Kit (Hypersensitive) offers low picogram sensitivity for immunoblotting via horseradish peroxidase (HRP) chemiluminescence. Its extended signal duration and low background are optimized for detection of low-abundance proteins on nitrocellulose or PVDF membranes. The kit enables robust, reproducible protein detection and streamlined workflows for research applications.

• Pemetrexed in Translational Oncology: Mechanisms, Models, an

  2026-06-09

  This article explores how pemetrexed, a multi-targeted antifolate, is reshaping translational cancer research. By integrating mechanistic insights, gene expression profiling, and practical workflow guidance, it provides strategic recommendations for researchers tackling drug resistance and DNA repair vulnerabilities in malignant mesothelioma and beyond.

• Clasto-Lactacystin β-lactone: Precision Proteasome Inhibitor

  2026-06-09

  Clasto-Lactacystin β-lactone empowers researchers with potent, irreversible proteasome inhibition for dissecting protein degradation in advanced models of viral inflammation, cancer, and neurodegeneration. This guide details data-backed workflows, cutting-edge applications, and troubleshooting strategies to maximize reliability in ubiquitin-proteasome pathway research.

• Phalloidin (B7678): Technical Use Guide for F-Actin Stabiliz

  2026-06-08

  Phalloidin (B7678) is used for high-affinity stabilization and imaging of filamentous actin in fixed or permeabilized samples, providing robust cytoskeleton visualization for cell biology research. It is not suitable for live-cell studies or experiments requiring reversible actin binding. Researchers should apply it where static analysis of actin structure is required.

• ETS1 Regulates Mitophagy in BPD via SENP2/HSPA8/FUNDC1 Axis

  2026-06-08

  This study identifies ETS1 as a novel transcriptional regulator that mitigates bronchopulmonary dysplasia (BPD) by suppressing mitochondrial damage-induced mitophagy through the SENP2/HSPA8/FUNDC1 pathway. The findings provide mechanistic insights into chaperone-mediated autophagy in neonatal lung disease, offering new molecular targets for therapeutic intervention.

• Axitinib (AG 013736): Selective VEGFR Inhibitor for Cancer R

  2026-06-07

  Axitinib (AG 013736) is a highly selective, orally bioavailable inhibitor of VEGFR1, VEGFR2, and VEGFR3. It demonstrates nanomolar potency in angiogenesis inhibition assays and robust tumor growth suppression in xenograft models, supporting precision cancer biology research.

16383 records 1/1093 page Next 12345 下5页 Last page